The FDA has approved a supplement to NDA 213871 for Cibinqo (abrocitinib), the Pfizer oral JAK1 inhibitor. The application database entry identifies the sponsor and the molecule and records the action as supplemental to the existing licence.
A supplemental approval modifies something about an already-licensed product — manufacturing, labelling, a presentation, occasionally an indication — and the entry alone does not say which. Abrocitinib's licensed indication in the US is moderate-to-severe atopic dermatitis, and this record does not establish a rheumatological indication.
The reason it belongs on a rheumatology desk is the class. Abrocitinib carries the boxed warning shared across JAK inhibitors, covering serious infection, mortality, malignancy, major adverse cardiovascular events and thrombosis, derived largely from the tofacitinib ORAL Surveillance trial in rheumatoid arthritis. Any label action on a JAK inhibitor is worth checking against that warning, because changes to the class labelling propagate across products a rheumatologist does prescribe.
In India, abrocitinib is available under CDSCO approval for atopic dermatitis, and the US action changes nothing about that position.
- Read the current prescribing information rather than inferring what the supplement changed
- This does not create a rheumatological indication for abrocitinib
- JAK class labelling changes propagate — check whether the boxed warning text moved
- The class warning derives from a rheumatoid arthritis trial, which is why it matters to this desk
- CDSCO status in India is unchanged by a US supplemental approval
Why it matters
Label actions on any JAK inhibitor can carry class-wide warning changes that reach the agents rheumatologists prescribe.
Don't overread it
A supplemental approval is an administrative action on an existing licence and carries no new efficacy or safety finding in itself.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free